首页> 外文期刊>Therapeutic Drug Monitoring >Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters.
【24h】

Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters.

机译:使用具有NPEM2群体药代动力学参数的贝叶斯模型估计,预测成人精神病患者中丙戊酸盐的浓度。

获取原文
获取原文并翻译 | 示例
       

摘要

Valproate serum concentrations between 45 and 125 microg/mL are associated with the drug's efficacy in acute mania. Adaptive control dosing of valproate has not been fully studied in psychiatry. The objective of this study was to derive population pharmacokinetic (PK) parameters for valproate in healthy volunteers and to test the ability of these PK parameters to estimate concentrations in adult psychiatric patients using a Bayesian program. Population PK parameters for oral valproate were estimated from 18 PK studies in six healthy volunteers (1) using NPEM2. A Bayesian PK program using these population parameters was used to predict valproate concentration-time points in a second cohort of 21 adult psychiatry patients using 0, 1, or 2 prior concentrations. Estimated population parameters (mean +/- SD) were: Ka, 1.15+/-1.75/h; V, 0.14+/-0.042 L/Kg; and CL, 0.902+/-0.133 L/h. Bayesian valproate estimations using these parameters were negatively biased (underestimations) using zero prior concentration and unbiased using 1 or 2 prior concentrations. Mean error values (95% CI) in microg/mL for predictions using 0, 1, or 2 prior concentration-time points were -12.0 (-22.5, -1.5), -9.5 (-19.1, 0.1), and -2.5 (-11.1, 6.1), respectively, and mean absolute error values in microg/mL (95% CI) were 19.8 (12.6, 27.1), 16.3 (9.4, 23.3), and 10.1 (4.9, 15.2), respectively. Population parameters derived from healthy adult volunteers provided biased predictions of valproate concentrations in adult psychiatric patients. However, estimates using 1 or 2 valproate concentration time points predicted future concentrations that were precise and unbiased, given the wide therapeutic target range.
机译:丙戊酸血清浓度在45至125微克/毫升之间与该药物在急性躁狂症中的功效有关。精神病学尚未对丙戊酸的自适应控制剂量进行充分研究。这项研究的目的是推导健康志愿者中丙戊酸盐的人群药代动力学(PK)参数,并使用贝叶斯程序测试这些PK参数估算成人精神病患者浓度的能力。使用NPEM2,由六名健康志愿者(1)进行的18项PK研究估计了口服丙戊酸盐的人群PK参数。使用这些人口参数的贝叶斯PK程序被用来预测21名成年精神病患者第二组使用0、1或2先前浓度的丙戊酸盐浓度-时间点。估计的种群参数(平均值+/- SD)为:Ka,1.15 +/- 1.75 / h; V,0.14 +/- 0.042 L / Kg; CL为0.902 +/- 0.133L / h。使用这些参数的贝叶斯丙戊酸盐估计值使用零先前浓度负偏(低估),而使用1或2个先前浓度无偏。使用0、1或2个先前浓度时间点进行的预测的平均误差值(95%CI),以微克/毫升表示为-12.0(-22.5,-1.5),-9.5(-19.1,0.1)和-2.5( -11.1、6.1)和平均绝对误差值(以微克/毫升(95%CI)为单位)分别为19.8(12.6、27.1),16.3(9.4、23.3)和10.1(4.9、15.2)。来自健康成人志愿者的人群参数提供了成人精神病患者丙戊酸盐浓度的偏向预测。但是,考虑到较宽的治疗目标范围,使用1个或2个丙戊酸盐浓度时间点进行的估算可预测出精确且无偏见的未来浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号